A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Nature

Volumn 504, Issue 7478, 2013, Pages 138-142

  Johannessen, Cory M ^a,b,c   Johnson, Laura A ^a,b,e   Piccioni, Federica ^a   Townes, Aisha ^a   Frederick, Dennie T ^d   Donahue, Melanie K ^a   Narayan, Rajiv ^a   Flaherty, Keith T ^d   Wargo, Jennifer A ^d   Root, David E ^a   Garraway, Levi A ^a,b,c  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; B RAF KINASE; B RAF KINASE INHIBITOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DABRAFENIB; ENTINOSTAT; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; HISTONE DEACETYLASE INHIBITOR; ISOBUTYLMETHYLXANTHINE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NUCLEAR RECEPTOR NUR77; NUCLEAR RECEPTOR RELATED FACTOR 1; PANOBINOSTAT; RAF PROTEIN; SAHAD; TRANSCRIPTION FACTOR SOX10; TREMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; VORINOSTAT;

CYTOLOGY; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITION; SIGNAL; TUMOR;

AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CELL LINEAGE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN BIOPSY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL LINEAGE; CREB-BINDING PROTEIN; CYCLIC AMP; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MELANOCYTES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84889606709     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12688     Document Type: Article

References (27)

1. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
2. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
3. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).
4. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114 (2012).
5. Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. Nature Methods 8, 659-661 (2011).
6. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
7. Wood, K. C. et al. MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci. Signal. 5, rs4 (2012).
8. Aronov, A. M. et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362-6368 (2009).
9. Crews, C. M.,Alessandrini, A.&Erikson, R. L.The primary structure ofMEK,a protein kinase that phosphorylates the ERK gene product. Science 258, 478-480 (1992).
10. Girotti, M. R. et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158-167 (2012).
11. Kyriakis, J. M. et al. Raf-1 activates MAP kinase-kinase. Nature 358, 417-421 (1992).
12. Patriotis, C., Makris, A., Chernoff, J. & Tsichlis, P. N. Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc. Natl Acad. Sci. USA 91, 9755-9759 (1994).
13. Pham, C. D., Arlinghaus, R. B., Zheng, C. F., Guan, K. L. & Singh, B. Characterization ofMEK1phosphorylation by the v-Mosprotein. Oncogene10, 1683-1688 (1995).
14. Pierce, K. L., Premont, R. T. & Lefkowitz, R. J. Seven-transmembrane receptors. Nature Rev. Mol. Cell Biol. 3, 639-650 (2002).
15. Hayward, N. K. Genetics of melanoma predisposition. Oncogene 22, 3053-3062 (2003).
16. Walton, K. M., Rehfuss, R. P., Chrivia, J. C., Lochner, J. E. & Goodman, R. H. A dominant repressor of cyclic adenosine 39,59-monophosphate (cAMP)-regulated enhancer-binding protein activity inhibits the cAMP-mediated induction of the somatostatin promoter in vivo. Mol. Endocrinol. 6, 647-655 (1992).
17. Ahn, S. et al. A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. Mol. Cell. Biol. 18, 967-977 (1998).
18. Dumaz, N. et al. In melanoma, RAS mutations are accompanied by switching signaling fromBRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66, 9483-9491 (2006).
19. Garraway, L. A. et al. Integrative genomic analyses identifyMITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
20. Jané-Valbuena, J. et al. An oncogenic role for ETV1 in melanoma. Cancer Res. 70, 2075-2084 (2010).
21. Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T. & Fisher, D. E. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391, 298-301 (1998).
22. Wu, M. et al. c-Kit triggers dual phosphorylations, which couple activation and degradationof the essentialmelanocyte factor Mi. Genes Dev.14,301-312 (2000).
23. Hodgkinson, C. A. et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74, 395-404 (1993).
24. Yokoyama, S. et al. Pharmacologic suppression of MITF expression via HDadenyl cyclase inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res. 21, 457-463 (2008).
25. Haq, R. et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistancetoBRAFinhibition. Proc. NatlAcad.Sci.USA110, 4321-4326(2013).
26. Smith, M. P. et al. Effect ofSMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J. Natl. Cancer Inst. 105, 33-46 (2013).
27. Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clinical Cancer Res. 19, 1225-1231 (2013).